Journal profile · Nanoscience & Nanotechnology
Nanomedicine-Nanotechnology Biology and Medicine
ISSN 1549-9634 · eISSN 1549-9642 · Elsevier Inc. · NETHERLANDS · Quarterly · Founded 2005
Nanomedicine-Nanotechnology Biology and Medicine: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.08; hybrid open access; APC about USD 3,670; median 87 days to acceptance (111 articles, last 24 months); community-reported acceptance: about 31.25%; 92 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Nanomedicine-Nanotechnology Biology and Medicine is published by Elsevier Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Nanoparticle-Based Drug Delivery, Nanoplatforms for cancer theranostics and RNA Interference and Gene Delivery, together about 42.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.Nanomedicine: Nanotechnology, Biology, and Medicine aims to promote the interdisciplinary field of nanomedicine.The journal publishes topics including:artificial cellsregenerative medicinegene therapyinfectious diseasenanotechnologynanomedicinenanobiotechnologystem celltissue engineeringSub-categories include synthesis, bioavailability, and biodistribution of nanomedicines; delivery, pharmacodynamics, and pharmacokinetics of nanomedicines; imaging; diagnostics; improved therapeutics; innovative biomaterials; interactions of nanomaterials with cells, tissues, and living organisms; public health; toxicology; theranostics; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics; and bioinformatics.
From the journal's Aims & Scope
Research area (LetPub): Nanoscience & Nanotechnology
Editor-in-chief Zhen ChengPublisher website
Editorial board by country: 5 in mainland China (about 9%); most named United States 30, Mainland China 5, Singapore 5, Hong Kong, China 2, India 2 (53 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoparticle-Based Drug DeliveryMaterials Science19.2%
- Nanoplatforms for cancer theranosticsEngineering12.1%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology11%
- Advanced biosensing and bioanalysis techniquesBiochemistry, Genetics and Molecular Biology6.1%
- Graphene and Nanomaterials ApplicationsEngineering5.1%
- Nanoparticles: synthesis and applicationsMaterials Science4.6%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics3.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Nanoscience & Nanotechnology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Nanoscience & Nanotechnology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Nanoscience & Nanotechnology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.08LetPub ·
- Impact factor (publisher)
- 4.3Publisher website ·
- CiteScore 2026-06
- 10.3LetPub ·
- CiteScore (publisher)
- 10.3Publisher website ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.74LetPub ·
- h-index
- 106LetPub ·
- h-index
- 173OpenAlex ·
- i10-index
- 2,366OpenAlex ·
- 2-year mean citedness
- 2.15OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 23.04%LetPub ·
Volume
- Articles per year
- 80LetPub ·
Articles by year OpenAlex count · 4,128 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 132 | 22 | 45 |
| 2025 | 92 | 27 | 206 |
| 2024 | 65 | 25 | 371 |
| 2023 | 78 | 41 | 1,087 |
| 2022 | 131 | 45 | 2,174 |
| 2021 | 156 | 65 | 3,547 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
87 daysMedian, submission to acceptance · P25–P75 64 days – 141 days
- Acceptance to online
- median 3 days (111 articles)
- Submission to online
- median 91 days
- Sample
- 111 articles with submission and acceptance dates (258 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 monthsLetPub ·
- Average acceptance (community reports)
- 31.25%LetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- First decision after review
- 52 daysPublisher website ·
- Submission to acceptance
- 98 daysPublisher website ·
- Acceptance to publication
- 6 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,670 / EUR 3,430 / GBP 2,940 / JPY 455,190 | — | — | |
| Publisher website | USD 3,810 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 5,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
Article types accepted9, with length limits
- case studydicines in real-life context. Length of case studies should not exceed 3,500 words (including body text, and figure legends) with a maximum ofmain text ≤ 3,500 words
- editorialCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…Length not stated
- hypothesisCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…Length not stated
- letters to the editorCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…Length not stated
- opinionCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…Length not stated
- original articleCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…Length not stated
- perspectiveCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…Length not stated
- reviewCOMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,500 words (…main text ≤ 12,000 words
- technical noteing, nanotechnology law, etc. Length of technical notes should not exceed 2,000 words (including body text and figure legends), 5 figures, and 10main text ≤ 2,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Quarterly
- Founded
- 2005
- ISSN
- 1549-9634
- Electronic ISSN
- 1549-9642
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Nanomedicine-Nanotechnology Biology and Medicine
What CAS zone is Nanomedicine-Nanotechnology Biology and Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Nanomedicine-Nanotechnology Biology and Medicine is in Zone 3 of Medicine, and in Zone 3 of the minor category Medicine, Research & Experimental / Nanoscience & Nanotechnology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Nanomedicine-Nanotechnology Biology and Medicine?
The latest impact factor listed by LetPub is 4.08; CiteScore 10.3, h-index 173.
How long does peer review take at Nanomedicine-Nanotechnology Biology and Medicine?
Based on the dates recorded on 111 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 87 days (interquartile range 64–141 days); authors report an average review time of about 6 months; the community-reported acceptance is “about 31.25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Nanomedicine-Nanotechnology Biology and Medicine?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 5,000 words; Reference style: Numbered, in order of citation; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Nanomedicine-Nanotechnology Biology and Medicine based?
Of the 53 board members whose country the journal's board page names, 5 (about 9%) are in mainland China; the countries named most often are United States (30), Mainland China (5) and Singapore (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Nanomedicine-Nanotechnology Biology and Medicine?
According to LetPub and DOAJ records, Nanomedicine-Nanotechnology Biology and Medicine is indexed in SCIE and Scopus.
Is Nanomedicine-Nanotechnology Biology and Medicine open access, and what is the APC?
Nanomedicine-Nanotechnology Biology and Medicine is a hybrid journal. For open-access publication: APC about USD 3,670.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .